The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to professionals working in the field of cancer immunology and immunotherapy. Established in 1984,SITC is a 501(c)(3) not-for-profit organization with a growing constituency of academic, government, industry, clinical and basic scientists, and practitioners from around the world.
Through emphasis on high-caliber scientific meetings; dedication to education and outreach activities; focus on initiatives of major importance in the field; and commitment to collaborations with like-minded domestic and international organizations, government and regulatory agencies, associations and patient advocacy groups, SITC brings together all aspects of the cancer immunology and immunotherapy community.
It is the mission of the Society for Immunotherapy of Cancer to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.
Interaction/Integration: Facilitate the exchange of information and education among basic and translational researchers, practitioners, young investigators, societies and groups sharing the mission of SITC
Innovation: Challenge the thinking and seek the best research in the development of cancer immunotherapy
Translation: Facilitate the transfer of cancer immunology and immunotherapy research from the bench to the clinic and back
Leadership: Define what is new and important and effectively communicate it to all relevant stakeholders